IL46338A - Determination of serum creatinne - Google Patents
Determination of serum creatinneInfo
- Publication number
- IL46338A IL46338A IL46338A IL4633874A IL46338A IL 46338 A IL46338 A IL 46338A IL 46338 A IL46338 A IL 46338A IL 4633874 A IL4633874 A IL 4633874A IL 46338 A IL46338 A IL 46338A
- Authority
- IL
- Israel
- Prior art keywords
- sodium
- sulfate
- creatinine
- reagent
- detergent
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title abstract description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 42
- 229940109239 creatinine Drugs 0.000 claims abstract description 36
- 239000003599 detergent Substances 0.000 claims abstract description 19
- 229940075930 picrate Drugs 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004202 carbamide Substances 0.000 claims abstract description 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 238000004737 colorimetric analysis Methods 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 claims description 4
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- CXPOFJRHCFPDRI-UHFFFAOYSA-N dodecylbenzene;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1 CXPOFJRHCFPDRI-UHFFFAOYSA-N 0.000 claims description 2
- 229940080236 sodium cetyl sulfate Drugs 0.000 claims description 2
- 229950005425 sodium myristyl sulfate Drugs 0.000 claims description 2
- 229940067741 sodium octyl sulfate Drugs 0.000 claims description 2
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 claims description 2
- MWZFQMUXPSUDJQ-KVVVOXFISA-M sodium;[(z)-octadec-9-enyl] sulfate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCOS([O-])(=O)=O MWZFQMUXPSUDJQ-KVVVOXFISA-M 0.000 claims description 2
- HHURSJAUVYNJBT-UHFFFAOYSA-M sodium;heptadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCOS([O-])(=O)=O HHURSJAUVYNJBT-UHFFFAOYSA-M 0.000 claims description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 claims description 2
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 claims description 2
- WFRKJMRGXGWHBM-UHFFFAOYSA-M sodium;octyl sulfate Chemical compound [Na+].CCCCCCCCOS([O-])(=O)=O WFRKJMRGXGWHBM-UHFFFAOYSA-M 0.000 claims description 2
- HQCFDOOSGDZRII-UHFFFAOYSA-M sodium;tridecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCOS([O-])(=O)=O HQCFDOOSGDZRII-UHFFFAOYSA-M 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000031700 light absorption Effects 0.000 claims 6
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims 1
- 239000012086 standard solution Substances 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 210000002700 urine Anatomy 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 238000011156 evaluation Methods 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 238000007375 Jaffe assay Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- ABPBBOIVOUJALM-UHFFFAOYSA-M sodium;dodecyl sulfate;urea Chemical compound [Na+].NC(N)=O.CCCCCCCCCCCCOS([O-])(=O)=O ABPBBOIVOUJALM-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A colorimetric process for the quantitative determination of creatinine in blood serum or urine wherein an alkaline pH in the approximate range of 11.0 to 13.5 is maintained during colorimetry evaluation and in which urea and a detergent are caused to react simultaneously and synergistically with the serum or urine protein to prevent extraneous chromogen formation in the conventional alkaline-picrate reaction for creatinine.
[US3894843A]
Description
DETERMINATION OP SERUM CREATININE DETERMINATION OF SERUM CREATININE A colorimetric process for the quantitative determination of creatinine in blood serum or urine wherein an alkaline pH in the approximate range of 11.0 to 13.5 is maintained during colorimetry evaluation and in which urea and a · detergent is caused to react simultaneously and synergistically with the serum or urine protein to prevent extraneous chromogen formation in the conventional alkaline-picrate reaction for creatinine.
BACKGROUND OF THE INVENTION This invention relates to the analysis of body fluids for the quantitative determination of the creatinine conteni^ of the fluid, such as blood serum and urine.
. The quantitative determination of creatinine is a very valuable procedure in connection with biologic fluids such as blood serum' and urine, for the diagnosis of certain diseases. Creatinine is a waste product removed from the blood stream by the kidneys. Since creatinine is excreted only by way of the kidneys, for instance, kidney disease can be diagnosed from an increased creatinine content measured in the serum.
Quantitative creatinine determination also is useful in the diagnosis of urinary obstruction, intestinal obstruction,, and nephritis,, an inflamation of the kidneys caused by infection, the degenerative process or vascular disease.. In U.S. patent No. 3,705,013, there is discussed some features of critical creatinine determinations desired for accurate and effective diagnosis of diseases.
U.S. Patents 3,557,018 and 3,705,013 discuss many known methods for determination of creatinine in biologic fluids.
DESCRIPTION OF THE PRIOR ART Most current methods for the determination of creatinine in serum or urine rely on the development of a red-orange ^ color formed by the interaction of alkaline-picrate and creatinine, first reported by M. Jaffe in 1886 and applied by. Otto Folin to determination of urinary creatinine in 1904. Since that time, this method using the so-called "Jaffe reaction" has become the most commonly used method for creatinine analysis.
The Jaffe reaction is not considered specific for .. creatinine in the presence of protein, glucose, and a number of unknown substances present in normal human sera. Methods designed to improve specificity have, for the most part, relied on use of protein-free filtrates. In addition to utilization of protein-free filtrates, so-called "specific methods" for creatinine have been introduced in which the filtrate is used in adsorption-elution. techniques; see Brod, J. and Kotatko, J., J. Cas. Lek. Ces. 88,665 - Excerpta Medica, Amst. 3,477 (1950); Hare, R.S., Proc. Soc. Exp. Biol. N.Y., 74,148 (1950); Haugen, H.N. and Blegen, E.M., Scand.
J. Clin. Invest. 5,58 (1953) ; and Polar, E. and Metkoff, J., Clin. Chem. 11,763 (1965). The most common absorption media used have been hydrated aluminum silicate and ion-exchange ■ resin.
.The problems encountered with adsorption-elution techniques center around complex procedures to effect the adsorption and eliminated. - Alternate "specific" techniques have utilized reagents such as eerie sulfate with protein-free filtrates to obtain "destruction of interfering substances". See Kostir, J.V. and Rabek, V., Biochim. Biophys. Acta 5, 210 (1950) Kostir, J.V. and Sonka, J., Biochim. Biophys. Acta 8,86 (1952) and use of "creatinine destroying bacteria" - Dubos, R. and Miller, V.F., J. Biol. Chem. 121,427 (1937). The latter procedure is one in which serum protein-free filtrates are divided into two aliquots; one aliquot being treated with the "creatinine destroying bacteria", the other aliquot left untreated. Sub¬ sequent Jaffe reactions with both aliquots give different d al^sorbance readings. Subtracting the "bacteria-treated" from the "non-treated" aliquot value is assumed to yield a "true creatinine" value. Specificity cannot be satisfactorily proven by this method either.
More recently, attempts have been made to develop Jaffe reaction methods avoiding serum deproteinization which fall into two primary categories. The first involves a so-called "kinetic procedure" requiring critically-timed measurement of rate of formation of the reddish-orange Jaffe color represented by Larsen, K. , Clin. Chim. Acta 41, 209 (1972 ) . Problems arise with the need for relatively sophisticated kinetic measurement spectrophotometers and use of extremely short color development times (30-120 seconds) . Effects of interference by non-creat- inine, Jaffe-reactive chromogens cannot be entirely disproven, as appears from Raabo, E. and Walloe-Hansen, P., Scand. J. Clin 137,829 Lab. Invest. 29,297 (1972) and Heinegard, D. and Tiderstrorn, "" G. , Clin, Chim.. Acta 43,305 (1973).
The second avenue of approach consists of introduction^ of suppression of non-creatinine, Jaffe-positive chromogens 5 by varying reaction pH or incorporating reagents shown to suppress the effect of color interference by non-creatinine substances. Reagent blanks or running serums at two different pH's are an integral part of all of these approaches as • seen from Raabo, E. and Walloe-Hansen, P. Scand. J. Clin. Lab. 10 Invest. 29,297 (1972) ; Heinegard, D. and Tiderstrorn, G., Clin. Chim. Acta 43,305 (1973). The methods relying solely on the assumption that running parallel reactions on the same serum, one at a higher pH than the other, subtracting the low pH value from that of the higher pH, and then using 15 "the factor 2.3" as a correction for protein interference, as taught by Raabo, E. and Walloe-Hansen, P., Scand. J. Clin.
Lab. Invest. 29,297 (1972), based on a large number of comparisons with a previous specific method as taught by Brod, J. and Sirota, J. H., J. Clin. Invest. 27,645 (1948) leaves doubts .20 about accuracy primarily because of this statistically observed "2.3 factor" and complete reliance on specificity based on the two separate pH dependent reactions.
SUMMARY OF THE INVENTION With the above delineated problems of the prior art in mind, the invention provides a procedure for the detecti¾ creatinine which employs an alkaline picrate reagent which substitutes sodium phosphate for the more commonly used sodium hydroxide or lithium hydroxide. Urea is alkane OK incorporated into the alkaline picrate reagent. An aralkane sulfate detergent of sodium, potassium or lithium, such as sodium dodecyl sulfate (sodium lauryl sulfate) and sodium borate are added to the reagent. In this procedure, suppressio of interfering chromogens is maximized and the serum blank is eliminated.
It is believed that in the presence, of urea, the protein molecules change in configuration and unfold as a result of mild denaturation. This configuration change increases exposure of the protein molecule to binding with the sodium dodecyl sulfate with resulting decrease in blank activity.
Test results using the invention have correlated well with reference methods using filtrates and adsorption techniques. 9 DESCRIPTION OF SPECIFIC EMBODIMENTS The following description is given to enable persons skilled in the art to more clearly understand and practice the invention. They should not be considered as limitations . upon the scope of the invention but should be regarded as illustrative only.
The reagent formulations are as follows: A. Saturated picric acid solution - approximatel 15 grams added to warm distilled water until no , further dissolving is observed.
B. i. Sodium dodecyl sulfate solution - 4 grams/100 ml. ii. Sodium borate in sodium or potassium phosphate - ~~ ···.,; ... dibasic solution - 0.05 M of borate to, 0.05 M ·■·.'"■■ · phosphate. ■·,■'■ iii. Urea solution - 40 grams/100 ml.
In using these stock or prepared solutions, a first working solution is prepared consisting of two parts of the 40% urea solution combined with two parts of the 4% sodium dodecyl sulfate solution. A preferred alternate working . solution consists of one part of the urea solution with three parts of the sodium dodecyl sulfate solution. Then, one part of a said sodium dodecyl sulfate - urea solution is mixed with one part of the borate-phosphate buffer solution and buffered using sodium hydroxide to a pH of about 12.4. The second working solution comprises the saturated picric acid solution.
Prior to use, four parts of the first working solution are mixed with one part of the saturated picric acid solution to provide a single alkaline picrate reagent.
In the creatinine determination procedure using the invention, 0.01 to 2.0 ml of sample has been used with 0.2 to 25.0 ml of final mixed reagent. Preferably, however, 0.1 to 0.2 ml of sample with 4.0 ml of final reagent is used.
In this preferred procedure, 4.0 ml of alkaline picrate reagen "is introduced into a suitable test tube and pre-incubated at- 37° Centrigrade for 3 to 5 minutes. Then, 0.1 or 0.2 ml of sample is mixed into the reagent and incubation at 37° Centrigrade maintained for from 10 to 30 minutes. Preferably, such incubation is maintained for 15 minutes.
^ The incubated solution then is introduced into a colorime or spectrophotometer against a blank and light absorpt of the thusly formed creatinine picrate is read at 490 to 535 nm. Preferably, the reading is made at 500 nm. Then, one ca calculate the value of unknown against primary aqueous standard or secondary protein-based standard run in conjunctio with the unknown using the following formula: (1) Value of Unknown ?η¾η^"^, * value of standar O.D. Standard The specific example given above is capable of being varied in certain respects within the parameters of the invention. The alkaline picrate reagent can be buffered to within a pH range of 11.0 to 13.5 by selective mixing of the buffer solution, to wit, the sodium borate in the sulfate solution as mentioned. Optical density measurements can be other modifications may occur to the skilled artisan relating to a particular material formulation to utilize the essential teachings of the invention. For instance, other detergents which may be used are: sodium octyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium cetyl sulfate, sodium myristyl sulfate, sodium octadecyl sulfate, sodium oleyl sulfate, sodium tridecyl sulfate, potassium lauryl sulfate and dodecyl benzene sulfate.
The analagous potassium or lithium salts are equally useful.. Generally, the detergent may be characterized as an aralkane sulfate of sodium, potassium or lithium.
What is claimed is:
Claims (15)
1. » A colometric process for the determination of creatinine in a biologic fluid sample containing proteins comprising, A. adding an alkaline piorate reagent to the biologic fluid which forms a colored complex having a characteristic wavelength of maximum light absorption with the creatinine in said fluid, adding ftirther an alkane or aralkane sulfate detergent of sodium potassium or lithium, while preventing the interference of protein wit the desired determination by forming urea-protein complexes which prevent formation of extraneous chroinogeus of a non-croatiuine character) B« measuring the degree of light absorption at said characteristic wavelength; and C. determining the creatinine concentration in said fluid by comparing the measured degree Of light absorption with values of light absorption obtained from standard aqueous solutions containing the reagent and known creatinine concentrations*
2. The process of claim 1 vherein ure is added to the sample prior to oolorimetric determinations being made in an amount sufficient to form such protein complexes* (
3. The process of claim 2 wherein a detergent is added to the urea and the combination is then added to sample
4. The process of claim 3 wherein the detergent selected is sodium octyl sulfate.
5. The process of claim 3 wherein the detergent selected is sodium tetradecyl sulfate.
6. The process of claim 3 wherein the detergent selected is sodium heptadecyl sulfate. (
7. The process of claim 3 wherein the detergent selected is sodium cetyl sulfate.
8. The process of claim 3 wherein the detergent selected is sodium dodecyl sulfate.
9. The process of claim 3 wherein the detergent selected is sodium myristyl sulfate.
10. The process of claim 3 wherein the detergent selected is. sodium octadecyl sulfate. ( 137,829
11. The process of claim 3 wherein the detergent selected is sodium oleyl sulfate.
12. The process of claim 3 wherein the detergent selected is sodium tridecyl sulfate.
13. The process of claim 3 wherein the detergent selected is dodecyl benzene sulfate.
14. The process of claim 3 wherein the detergent alkane or comprises a sodium, potassium or lithium/aralkane sulfate solution. )
15. The process of claim 3 wherein sample size of sample is maintained from 0.01 to 2.0 ml. The process of claim 3 wherein the volume of reagent is maintained from 0.2 to 25.0 ml. The process of claim 3 wherein pH is maintained from 11.0 to 13.5 during colorimetry. The process of claim 3 wherein a buffer is added to the reagent to maintain a pH of between 11.0 to 13.5 during colorimetry. ( A reagent system for use in the determination of creatinine in a biological fluid sample containing proteins and in which the creatinine concentration in the sample is determined by comparing the measured degree of light absorption with values of light absorption obtained from standard solutions/ comprising: A. Saturated picric acid solution in distilled water; and B. i. urea solution; ii. a buffered solution of sodium borate in a sulphate salt of sodium or potassium buffered to a pH of between 11.0 to 13.5; and alkane or iii. an/aralkane sulphate detergent solution. The reagent system of claim 19 in which. the solution of Part A is mixed with the solution of Part B to provide an alkaline picrate reagent used in the creatinine determination. ( ( 137,829 The reagent system as claimed in claim 20 in which the alkaline picrate reagent is pre- incubated at 37° C. and then the sample is introduced into the reagent and incubated at for from 10 to 30 inubes. Tel-Aviv, December 24, 1974
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US447864A US3894843A (en) | 1974-03-04 | 1974-03-04 | Determination of serum creatinine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL46338A0 IL46338A0 (en) | 1975-03-13 |
| IL46338A true IL46338A (en) | 1977-10-31 |
Family
ID=23778053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL46338A IL46338A (en) | 1974-03-04 | 1974-12-25 | Determination of serum creatinne |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3894843A (en) |
| JP (1) | JPS50120897A (en) |
| BE (1) | BE824205A (en) |
| CH (1) | CH594245A5 (en) |
| DE (1) | DE2504994A1 (en) |
| ES (1) | ES434127A1 (en) |
| FR (1) | FR2263515A1 (en) |
| GB (1) | GB1445954A (en) |
| IL (1) | IL46338A (en) |
| NL (1) | NL7416476A (en) |
| SE (1) | SE7501016L (en) |
| ZA (1) | ZA75224B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4111657A (en) * | 1977-01-21 | 1978-09-05 | American Monitor Corporation | Creatinine assay and reagent system |
| US4529708A (en) * | 1983-04-07 | 1985-07-16 | American Monitor Corporation | Assay for the determination of creatinine |
| US4539295A (en) * | 1983-06-30 | 1985-09-03 | Beckman Instruments, Inc. | Binary kinetic assay method and apparatus |
| US4818703A (en) * | 1985-10-23 | 1989-04-04 | Pizzolante John M | Stabilized alkaline picrate reagent for jaffe creatinine determination |
| US4950611A (en) * | 1987-06-26 | 1990-08-21 | Beckman Instruments | Cold stable liquid creatinine reagent |
| CN101466875B (en) * | 2006-06-12 | 2011-01-05 | 日矿金属株式会社 | Rolled copper or copper alloy foil having roughened surface and roughening method of the rolled copper or copper alloy foil |
| SG10201913421YA (en) | 2014-02-28 | 2020-03-30 | Nitto Denko Corp | Urinalysis device and dry reagent for quantitative urinalysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1648977A1 (en) * | 1967-07-20 | 1970-08-13 | Merck Anlagen Gmbh | Color reagent for the determination of creatinine |
| US3705013A (en) * | 1970-01-05 | 1972-12-05 | Xerox Corp | Analytical procedures and compositions therefor |
| US3682586A (en) * | 1971-03-10 | 1972-08-08 | Union Carbide Corp | Process for the determination of creatinine body fluids |
-
1974
- 1974-03-04 US US447864A patent/US3894843A/en not_active Expired - Lifetime
- 1974-12-18 NL NL7416476A patent/NL7416476A/en unknown
- 1974-12-25 IL IL46338A patent/IL46338A/en unknown
-
1975
- 1975-01-08 BE BE6044885A patent/BE824205A/en unknown
- 1975-01-13 ZA ZA00750224A patent/ZA75224B/en unknown
- 1975-01-24 GB GB321475A patent/GB1445954A/en not_active Expired
- 1975-01-24 ES ES434127A patent/ES434127A1/en not_active Expired
- 1975-01-30 FR FR7502948A patent/FR2263515A1/fr not_active Withdrawn
- 1975-01-30 SE SE7501016A patent/SE7501016L/xx unknown
- 1975-01-31 JP JP50012630A patent/JPS50120897A/ja active Pending
- 1975-01-31 CH CH127875A patent/CH594245A5/xx not_active IP Right Cessation
- 1975-02-06 DE DE19752504994 patent/DE2504994A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL46338A0 (en) | 1975-03-13 |
| GB1445954A (en) | 1976-08-11 |
| ES434127A1 (en) | 1977-03-01 |
| DE2504994A1 (en) | 1975-09-11 |
| AU7596374A (en) | 1976-06-03 |
| SE7501016L (en) | 1975-09-05 |
| CH594245A5 (en) | 1977-12-30 |
| ZA75224B (en) | 1976-08-25 |
| FR2263515A1 (en) | 1975-10-03 |
| BE824205A (en) | 1975-07-08 |
| US3894843A (en) | 1975-07-15 |
| NL7416476A (en) | 1975-09-08 |
| JPS50120897A (en) | 1975-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trivedi et al. | New enzymatic method for serum uric acid at 500 nm. | |
| Schade et al. | Bound iron and unsaturated iron-binding capacity of serum; rapid and reliable quantitative determination | |
| Iwata et al. | New micro-turbidimetric method for determination of protein in cerebrospinal fluid and urine. | |
| US3950226A (en) | Novel reagent and method for the determination of urea in biological fluids | |
| Rej et al. | Interference by Tris buffer in the estimation of protein by the Lowry procedure | |
| Walser | Determination of free magnesium ions in body fluids. Improved methods for free calcium ions, total calcium, and total magnesium | |
| EP0215170B1 (en) | Single color reading method for determining fructosamine | |
| WO1992011524A2 (en) | Reagent and methods for calcium determination | |
| US3894843A (en) | Determination of serum creatinine | |
| JPH0425000B2 (en) | ||
| CA1089338A (en) | Creatinine assay and reagent system | |
| Doumas et al. | Chemical nature of a synthetic bilirubin conjugate and its reactivities in the total and direct reactions by the Jendrassik-Gróf method. | |
| JPWO2002086151A1 (en) | Biological component measurement method | |
| Kekki | Microdetermination of Amino Nitrogen as Copper Complexes a Modification for Plasma and Urine | |
| US4529708A (en) | Assay for the determination of creatinine | |
| US5219760A (en) | Process for the determination of iron | |
| Van Pilsum | Determination of creatinine and related guanidinium compounds | |
| US4211531A (en) | Colorimetric cholesterol assay | |
| Lawrie | The excretion of l (—)-tyrosine in urine | |
| US3778384A (en) | Diagnostic composition for the quantitative determination of glucose | |
| JPH0690207B2 (en) | Method and combined reagent for quantifying iron in serum | |
| Ujiie et al. | A new micromethod for colorimetric determination of zinc in serum | |
| Harrison et al. | Biomass measurements: protein | |
| Iron Panel of the International Committee for Standardization in Haematology | Revised recommendations for the measurements of the serum iron in human blood | |
| JP2589088B2 (en) | Determination of anti-streptolysin O |